Sumitomo Dainippon Pharma Co.

Sumitomo Pharma Co., Ltd. is a research-driven pharmaceutical company focused on the development of innovative treatments in the areas of oncology, psychiatry and neurology, and other specialty fields. The company utilizes a diverse range of modalities, including small molecule drugs and regenerative medicine and cell therapies, to address areas of high unmet medical need. Historically formed through the merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals, the organization operates with a global perspective, maintaining significant business platforms and research and development capabilities in both Japan and the United States. Its approach combines deep scientific expertise with a commitment to value creation aimed at improving healthcare outcomes worldwide.

For patients, healthcare providers, and global partners, Sumitomo Pharma serves as a key developer of therapeutic solutions that target complex and often chronic health conditions. By leveraging a robust commercial platform in Japan and strategic operations in the U.S., the company works to maximize the value of its product portfolio, which includes treatments for conditions such as advanced prostate cancer, overactive bladder, and various neurological disorders. The company’s focus on sustainability management and innovative R&D ensures that it remains an essential contributor to the medical community, consistently advancing new therapies that support fuller lives and better health for people across the globe.